Pulse Biosciences Inc.'s (PLSE) CellFX System has received Investigational Device Exemption approval from the FDA and a pivotal study evaluating this device in the treatment of sebaceous hyperplasia lesions has been initiated.
from RTT - Biotech https://ift.tt/3jlFTd1
via IFTTT
No comments:
Post a Comment